Tivic Health Systems Secures $8.4M in Series B to Revolutionize Bioelectronic Medicine

Tivic Health Systems is excited to announce a transformative milestone as the company successfully raised $8,400,000 in its latest funding round. This important capital infusion will empower Tivic to accelerate its mission of advancing bioelectronic medicine—a field that is set to revolutionize healthcare by offering innovative, drug-free therapeutic solutions for inflammatory chronic health conditions. At the core of Tivic’s groundbreaking work is its patented technology platform, which leverages targeted stimulation on the trigeminal, sympathetic, and vagus nerve structures. This non-invasive and precisely aimed approach not only ensures high safety profiles and low risk but also provides versatile applications that benefit both consumers and providers across various therapeutic scenarios. The funds raised are strategically allocated to expand research and development, propel commercialization efforts, and bolster the company’s operational framework. A significant portion of the investment will support the further advancement and market penetration of ClearUP, Tivic’s flagship product. ClearUP, an FDA-approved and award-winning handheld bioelectronic sinus device, is already making waves in the health tech arena with its clinically proven efficacy and doctor recommendations. It is readily available via online retailers and commercial distributors, highlighting Tivic’s commitment to accessibility and patient-centered care. By strengthening its financial foundation, Tivic Health Systems is poised to scale its innovative solutions, ensuring that the promise of bioelectronic medicine is fully realized to improve overall health, fight disease, and enhance the vibrancy of life for countless individuals. This funding round marks a significant leap forward as Tivic continues to lead the charge into a new era of medical treatments.